Giorgio Attardo, MD, leads discovery research at Avid Radiopharmaceuticals Inc. His team has delivered several beta-amyloid tracers for exploratory clinical trials and completed the non-clinical development of T807, a first in class tau imaging agent, for full clinical development.

Before joining Avid, Dr. Attardo held positions of increasing responsibility to the appointment of senior director at both Chlorion Pharma and Gemin X Pharmaceuticals. His R&D effort at Gemin X provided two oncology drug candidates, Obatoclax and Teglarinad, which were pivotal assets in the acquisition of Gemin X by Cephalon. Prior to Gemin X, Dr. Attardo was associate director of  chemistry at BioChem Pharma and Shire Pharmaceuticals.

Dr. Attardo's doctorate from McGill University and industrial postdoctoral research at BioChem Pharma focused on the design and synthesis of novel oncolytics. He is an inventor on more than 60 patents and patent applications and has co-authored over 40 publications and 60 conference presentations.